1100748-84-2

Basic information

• Product Name: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester
• Synonyms: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester;1-AMino-7-Boc-7-azaspiro[...;1-AMino-7-Boc-7-azaspiro[3.5]nonane;tert-butyl 1-aMino-7-azaspiro[3.5]nonane-7-carboxylate
• CAS NO: 1100748-84-2
• Molecular Formula: C₁₃H₂₄N₂O₂
• Molecular Weight: 240
• Mol File: 1100748-84-2.mol

Chemical Properties

• Boiling Point: 337℃
• Flash Point: 157℃
• Appearance: /
• Density: 1.08
• PKA: 10?+-.0.20(Predicted)
• CAS DataBase Reference: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester(1100748-84-2)
• EPA Substance Registry System: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester(1100748-84-2)

Safety Data

• Hazardous Substances Data: 1100748-84-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester is used as a synthetic reagent for the development of novel bioactive molecules and drug candidates. Its unique spiro scaffold structure provides a foundation for the creation of new compounds with potential therapeutic applications.
Used in Drug Discovery:
1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester is used as a key intermediate in the synthesis of a series of spiro scaffolds, which are essential for the identification and development of new drugs with improved efficacy and selectivity. The compound's versatility in chemical modifications enables the exploration of various structural variations, leading to the discovery of innovative therapeutic agents.

Upstream product

• 1100748-83-1 tert-butyl 1-(benzylamino)-7-azaspiro[3.5 ]nonane-7-carboxylate 

Downstream Products

• 1100748-78-4 1-amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester hydrochloride 
• 1100748-83-1 tert-butyl 1-(benzylamino)-7-azaspiro[3.5 ]nonane-7-carboxylate 

Relevant articles and documents

ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES

The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

Synthesis of four novel natural product inspired scaffolds for drug discovery

Inspired by the novel spiro structures of a number of bioactive natural products such as the histrionicotoxins, a series of novel spiro scaffolds have been designed and robust syntheses developed. The scaffolds are ready-to-use building blocks and can be easily prepared on a 5-20 g scale. They contain two amino groups (one Boc-protected) and have been designed for ease of conversion to a lead generation library, using either amide formation or reductive amination procedures. The synthesis of the 1,9-diazaspiro[5.5]undecane and 3,7-diazaspiro[5.6]dodecane ring systems was achieved using RCM as the key step. A simple workup procedure is reported for the removal of highly colored ruthenium residues. The synthesis of the 1,8-diazaspiro[4.5]decane scaffold has been achieved using a bromine-mediated 5-endo cyclization of the corresponding 4-aminobutene intermediate under acidic conditions. This is the first example of this type of cyclization to be reported. A novel mechanism involving a bromine transfer reaction from an initially formed bromonium ion to a neighboring nitrogen atom is suggested as the reason for the failure of this type of reaction under "normal" bromination conditions. An unusual rearrangement of a 1-acyl-1,9-diazaspiro[5.5]undecane to the corresponding 9-acyl-1,9-diazaspiro[5.5]undecane is reported.